Lungs and bone (marrow), organs of predilection for (primary/ metastatic) EWS, represent predominant CXCL12 sources Currently, after having demonstrated anti-tumor activity in pre-clinical and animal tumor models, several CXCR4 antagonists are being evaluated in clinical studies for treatment of patients with hematological and solid tumors. Here, EWSR1 is linked to neoplasm.